Mind the Gap: Telemedicine Effectively Bridges Patients With OUD to Treatment

INTRODUCTION

- Individuals with substance use disorders (SUD) face persistent barriers to treatment access, especially those with co-occurring conditions. [1]
- Temporary health policy changes during the COVID-19 public health emergency permitted initiation of medication for opioid use disorder (MOUD) via audio/visual telehealth modalities without need for in-person examination.
- In response, the UPMC Department of Emergency Medicine and UPMC Health Plan created the UPMC Medical Toxicology Telemedicine Bridge Clinic (Bridge Clinic) to rapidly engage OUD patients with early treatment.
- Prior analysis of the program showed high patient engagement with Bridge Clinic visits and MOUD. [2]
- We conducted a follow-up analysis to assess clinical outcomes.

METHODS

- N=150 UPMC Health Plan members treated by the Bridge Clinic between October 2020 and February 2022 who had 6 months of continuous insurance coverage before and after their Bridge Clinic visit were included.
- Pre/post analysis to assess changes in utilization and MOUD adherence at 30-, 90-, and 180-days.
- Utilization included overall and SUD-specific claims and was measured as visits per 1000 members.
- MOUD adherence on buprenorphine was measured using proportion of days covered (PDC).


RESULTS

- Overall and SUD-specific outpatient behavioral health (BH) and laboratory test utilization increased significantly at all follow-up time points (Table 1).
- Favorable trends were observed for other overall and SUDspecific services, but these trends were not significant at all follow-up time points (Table 1 & Figure 1).
- 91% of members filled a buprenorphine prescription within one-month post-visit and 95% filled a prescription by six months post-visit.
- PDC outcomes improved significantly at all follow-up time points (Table 1).

Table 1. Utilization per 1000 and Proportion of Days Covered (PDC) Outcomes Before and After Bridge Clinic Visit

Utilization per 1000 and	30-Days		90-Days		180-Days	
PDC (%) Categories	Pre	Post	Pre	Post	Pre	Post
Lab Testing	420	880*	373	682*	356	659*
Outpatient BH	413	1100*	320	782*	275	620*
Inpatient BH	20	7	20	4*	16	6
Emergency	227	127	162	118	151	123
SUD-Lab Testing	220	547*	236	473*	218	455*
SUD-Outpatient BH	300	1053*	253	740*	219	569*
SUD-Emergency	93	13*	53	27*	40	31
SUD-Primary Care	233	393*	264	322	266	303
Average PDC	20.7	65.1**	24.3	53.6**	24.8	50.8**
Median PDC	0.0	73.3**	0.0	54.4**	1.7	50.6**
Proportion PDC > 60%	9.8	60.1**	23.1	47.6**	20.3	44.8**
Proportion PDC > 80%	9.8	42.7**	9.8	35.0**	12.6	31.5**

*Post-period change significant at p < 0.10; **Post-period change significant at p < 0.001.



CONCLUSION

- Use of the Bridge Clinic was associated with rapid MOUD initiation, significant increases in buprenorphine adherence, and improved utilization outcomes for primary care, outpatient behavioral health, inpatient behavioral health, and emergency services.
- Results suggest that the Bridge Clinic is an effective delivery model for initiating MOUD and supporting long-term treatment for OUD.
- Findings are consistent with outcomes of other tele-OUD programs and demonstrate the potential of tele-OUD to serve as a low-barrier mechanism for evidence-based treatment and provide more rapid, equitable access to critical health care services. [3]

Limitations: Small sample size, pre-post design, PDC calculations did not account for drug equivalences or multiple types of MOUD.

AUTHORS & DISCLOSURES

Michael Lynch, MD^{1,2,3}, Dominic L. Vargas, MBA¹, Mary E. Winger, PhD, MPH¹, Justin E. Kanter, MA¹, Jessica Meyers, MSEd¹

1. UPMC Health Plan; 2. UPMC Department of Emergency Medicine; 3. University of Pittsburgh School of Medicine

The authors have no conflicts to disclose.

REFERENCES

- I. Novak P, Feder KA, Ali MM, Chen J. Behavioral health treatment utilization among individuals with co-occurring opioid use disorder and mental illness: Evidence from a national survey. J Subst Abuse Treat. 2019 Mar;98:47-52. doi: 10.1016/j. jsat.2018.12.006. Epub 2018 Dec 19. PMID: 30665603; PMCID: PMC6350939
- 2. Lynch MJ, Houck P, Meyers J, Schuster J, Yealy DM. Use of a Telemedicine Bridge Clinic to Engage Patients in Opioid Use Disorder Treatment. J Addict Med. 2022 Sep-Oct 01;16(5):584-587. doi: 10.1097/ADM.0000000000000967. Epub 2022 Mar 2. PMID: 35258040.
- 3. Guillen AG, Reddy M, Saadat S, Chakravarthy B. Utilization of Telehealth Solutions for Patients with Opioid Use Disorder Using Buprenorphine: A Scoping Review. Telemed J E Health. 2022 Jun;28(6):761-767. doi: 10.1089/tmj.2021.0308. Epub 2021 Oct 29. PMID: 34714172.

